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Abstract
Identification of the underlying genetic, cellular, and biochemical basis of lipid metabolic 
disorders provides an opportunity to deploy corrective, mechanism-targeted, topical therapy. We 
assessed this therapeutic approach in two patients with Congenital Hemidysplasia with 
Ichthyosiform Erythroderma and Limb Defects (CHILD) syndrome, an X-linked dominant 
disorder of distal cholesterol metabolism. Based upon the putative pathogenic role of both 
pathway-product deficiency of cholesterol and accumulation of toxic metabolic intermediates, we 
assessed the efficacy of combined therapy with lovastatin and cholesterol. We also evaluated the 
basis for the poorly understood, unique lateralization of the cutaneous and bone malformations of 
CHILD syndrome by analyzing gene activation in abnormal and unaffected skin. Ultrastructural 
analysis of affected skin showed evidence of both cholesterol depletion and toxic metabolic 
accumulation. Topical treatment with lovastatin/cholesterol (but not cholesterol alone) virtually 
cleared skin lesions by 3 months, accompanied by histologic and ultrastructural normalization of 
epidermal structure and lipid secretion. The unusual lateralization of abnormalities in CHILD 
syndrome reflects selective clearance of keratinocytes and fibroblasts that express the mutant 
allele from the unaffected side. These findings validate pathogenesis-based therapy that provides 
the deficient end-product and prevents accumulation of toxic metabolites, an approach of potential 
utility for other syndromic lipid metabolic disorders.
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INTRODUCTION
The ichthyoses are a group of inherited scaling skin disorders of diverse etiologies (Oji et 
al., 2010), which share a permeability barrier abnormality that parallels the severity of the 
clinical phenotype (rev. in (Elias et al., 2008; Moskowitz et al., 2004; Schmuth et al., 
2007)). Current treatment of the ichthyoses remains symptomatic and largely directed 
towards reducing the scaling component. This approach is often ineffective, may be 
accompanied by toxicity (e.g., with systemic retinoids), and is intuitively counterproductive, 
since the hyperkeratosis and hyperplasia likely reflect an epidermal homeostatic response to 
re-establishing a competent barrier (Elias, 2010). Use of recombinant protein replacement or 
gene therapy for genodermatoses remains remote, due to the: i) widespread nature of the 
cutaneous phenotype; ii) difficulties in transcutaneous drug delivery; iii) discomfort of 
injections needed to bypass the largely-impenetrable epidermal barrier; iv) enormous costs 
of the required ‘designer approach’; and v) uncertain long-term risks of viral transduction.
Recent advances in our understanding of the underlying genetic, cellular, and biochemical 
basis of many forms of ichthyosis (Elias et al., 2010) present an alternative, intriguing 
opportunity to initiate pathway- or mechanism-based therapy for many of these disorders. In 
syndromic lipid metabolic disorders, the cutaneous and extracutaneous manifestations often 
reflect not only deficiency of pathway product (i.e., cholesterol, free fatty acids, or 
ceramides), but also accumulation of toxic pathway metabolites (Cooper et al., 2003; Elias 
et al., 2008; Holleran et al., 1994; Kelley and Herman, 2001; Rizzo et al., 2010; Zettersten 
et al., 1998). In inherited disorders of distal cholesterol metabolism, attempts are underway 
to treat extracutaneous components by oral co-administration of cholesterol and/or statins 
(Chan et al., 2009; Haas et al., 2001; Szabo et al., 2010). Yet, this approach will inevitably 
be hampered by first-pass hepatic metabolism of statins, as well as intrahepatic 
incorporation of oral cholesterol into lipoprotein particles, which are unable to traverse the 
blood-brain barrier or access peripheral tissues without LDL receptors, such as the epidermis 
(Ponec et al., 1992).
We hypothesized that topical application of these agents could bypass hepatic first-pass 
metabolism, allowing direct access not only to the skin, but perhaps to extracutaneous 
tissues as well. If validated, such topical pathogenesis (pathway)-based therapy would 
display substantial inherent advantages, including: i) disease-targeted and mechanism-based 
specificity; ii) inherent safety; iii) relatively low cost, in comparison to small molecule, 
recombinant protein or gene therapy; and iv) exploitation of the ready accessibility and 
visibility of the skin to assess therapeutic efficacy and safety.
We have now validated this therapeutic approach in two unrelated patients with a syndromic 
disorder of distal cholesterol metabolism (Congenital Hemidysplasia with Ichthyosiform 
erythroderma and Limb Defects, CHILD syndrome, OMIM #308050), which includes a 
notoriously unresponsive ichthyosis. CHILD syndrome is an X-linked dominant disorder 
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caused by mutations in NAD(P)H steroid dehydrogenase-like (NSDHL), which encodes a 
member of the enzyme complex that removes the C-4 methyl group from lanosterol (Fig. 1) 
(Grange et al., 2000; Kelley and Herman, 2001). Most affected individuals are female, since 
the disorder is largely embryonic lethal in males. Clinical manifestations range from 
localized skin disease (‘CHILD nevus’) to extensive limb malformations, which entirely or 
largely localize to one side of the body, often with a sharp midline demarcation 
(lateralization) (Happle, 2006). More limited skin lesions may follow one or more lines of 
Blaschko, a recognized pattern of ectodermal development (Sun and Tsao, 2008). The basis 
for the unique lateralization in CHILD syndrome is unknown.
We report here that the skin lesions in both patients responded dramatically to topical co-
application of cholesterol and lovastatin (but not to cholesterol alone). The striking 
improvement through topical delivery supports the use of such topical, pathogenesis-based 
therapy for cutaneous, and possibly extracutaneous, manifestations of syndromic disorders 
of lipid metabolism.
RESULTS
Description of Cases
Patient 1—A 13-year-old girl was born with marked soft tissue and bone deformities, 
including digit-like protrusions on the distal aspects of the markedly-reduced left upper and 
lower extremities. Her skin displayed ichthyosiform, erythrodermic plaques on the left side 
of her body. At 3 years of age, her rudimentary left lower leg was amputated to allow fitting 
of a prosthesis. However, her ichthyosis involved the entire left thigh and stump (Fig. 2a), 
preventing her wearing the prosthesis due to persistent skin breakdown. She showed no 
cutaneous or bone defects of the right side. The patient was treated with petrolatum-based 
emollients without benefit. She neither tolerated nor improved with topical applications of 
keratolytics, retinoids, corticosteroids, or calcineurin inhibitors. At 9 years of age she 
developed an enlarging, pendulous tumor of the vulva and left inner thigh. Tumor sections 
histologically revealed verruciform xanthomatosis, which was debulked at 12 years of age. 
DNA sequencing from blood leukocytes showed a c.248G>A transition in exon 3 of one 
allele of NSHDL at Xq28, predicting the substitution p.Gly83Asp (G83D) and verifying the 
diagnosis of CHILD syndrome.
Patient 2—A 22-year-old woman was born with a severely malformed right lower 
extremity, necessitating amputation during early childhood, and malformations of the right 
hand with nail dystrophy. During the first few years of life, she developed inflamed, 
thickened skin on the dorsal aspect of the right hand that gradually extended to the right 
axilla (Fig. 2b). She had no abnormalities on the left side of her body, except for a small, 
scaling plaque between the left 3rd and 4th fingers. The patient also had neurosensory 
deafness of the right ear and severe lumbar scoliosis. She was treated for 17 years with 
topical emollients, steroid ointments or cryotherapy without significant improvement. DNA 
sequencing from blood leukocytes showed a nonsense mutation in exon 4 on one allele of 
the NSDHL gene (c.317C>A; p.S106X), verifying the diagnosis of CHILD syndrome. Hphl 
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digestion of the PCR fragment confirmed the predicted abnormal restriction pattern, which 
was not observed in controls (courtesy of Prof. K. Grzeschik, Marburg, Germany).
Efficacy and Mechanism of Pathogenesis (Pathway)-Based Therapy
Clinical observations—We first addressed the possibility that skin lesions in CHILD 
syndrome primarily reflect cholesterol (pathway end-product) deficiency alone, but found no 
clinical improvement after 3 months of treatment with twice daily topical 10% cholesterol in 
hydrophilic ointment. We next considered the possibility (supported by ultrastructural 
studies described below) that the cutaneous phenotype reflects both cholesterol deficiency 
and accumulation of toxic sterol metabolites. Lesional skin of both patients was treated 
twice daily with 2% lovastatin/2% cholesterol lotion. Decreased inflammation, skin 
thickening, and scaling was noted as early as 4–6 weeks in both patients, and the severity 
scores decreased by 72% (patient 1) and 79% (patient 2) by 3 months. By 6 months, treated 
skin largely normalized, but did not grow hair (Fig. 2a). Patient #1, now more than 1 year on 
therapy, uses the medication twice weekly with good control and is able to wear her 
prosthesis. Patient #2 has been treated for more than 17 months, now once to twice weekly, 
and shows residual hypopigmentation without inflammation or scaling (Fig. 2b). She has 
improved digital mobility, but little improvement in onychodystrophy, likely reflecting the 
inability of the compound to penetrate the nail. Patient #2 discontinued therapy for 15 days 
while on vacation without relapse. In both patients, the compounded lotion has been well-
tolerated. Laboratory testing 6 months after initiation of dual therapy revealed no changes in 
blood counts, hepatic function, creatinine or serum lipids.
Light and electron microscopic alterations—Baseline biopsy sections of skin lesions 
from both patients prior to treatment showed marked hyperkeratosis and acanthosis with 
absence of the granular layer and dermal foam cells (Fig. 2c, left). Ultrastructural 
assessment of these biopsies showed severe alterations in the epidermal lamellar body (lipid) 
secretory system. Individual organelles displayed few internal lamellae, which often fused 
prematurely into intracellular, multivesicular bodies that were incompletely secreted (Figs. 
3a-c). Partial failure of organelle secretion correlated with the presence of entombed 
organelle contents within corneocytes (Fig. 3c), and retention of acid lipase, an organelle 
content marker, within corneocytes (Fig. 4a). Finally, and as a result of impaired secretion, 
the stratum corneum extracellular matrix displayed a paucity of secreted lamellar material, 
interspersed with abundant non-lamellar vesicles (Fig. 3c; open arrows). In contrast, biopsy 
sections after 3 months of treatment showed a largely normal epidermis, with a prominent 
granular layer and orthokeratotic scale by light microscopy (Fig. 2c, right). Moreover, 
ultrastructural analysis showed nearly complete resolution of the structural abnormalities in 
the lamellar body secretory system, and normalization of secretion in both patients (Figs. 3d, 
3e and 4b).
A Subclinical Phenotype Persists in Clinically-Unaffected Sites
Pre-treatment biopsies also were obtained from a contralateral, ‘unaffected’ skin site in 
Patient #1. Although no visible ichthyosiform features could be appreciated either clinically 
or by light microscopy, ultrastructural images displayed mild abnormalities in lamellar body 
internal contents and lamellar bilayer organization, with the presence of lamellar/non-
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lamellar phase separation but not disordered secretion (Figs. 5a-c). These findings, though 
far less prominent than images from clinically-affected sites and without evidence of 
cytotoxicity, suggested that residual abnormalities persist in ‘uninvolved’ skin, prompting 
examination of gene expression in these affected vs. ‘unaffected’ contralateral sites.
Genetic Basis for Clinically Normal Skin in CHILD Syndrome
X-inactivation studies on peripheral blood leukocytes showed preferential Inactivation of 
one allele (89+2% of normal allele), consistent with skewing of X-inactivation. Genomic 
DNA sequencing from both sets of keratinocytes showed equal representation of both alleles 
(Fig. 6). However, RT-PCR on cDNA from keratinocytes and fibroblasts isolated from the 
affected versus clinically unaffected side in Patient #1 demonstrated exclusive expression of 
the mutant allele by affected cultured keratinocytes, while unaffected keratinocytes solely 
expressed the wild type allele (Fig. 6). Only the normal allele was expressed by unaffected 
fibroblasts, but fibroblasts from the clinically affected area expressed an approximately even 
distribution of normal and mutant alleles.
DISCUSSION
Discovery of genetic changes underlying thousands of disorders has increased our 
understanding of normal cell function, as well as the cellular and molecular abnormalities 
that lead to disease phenotypes. In addition, we can now consider the possibility of 
pathogenesis-based therapy. As our disease prototype to consider the feasibility of 
pathogenesis-based therapy, we chose CHILD syndrome, an X-linked dominant disorder of 
distal cholesterol synthesis. We show here that topical application of the deficient pathway 
end-product (cholesterol) is ineffective, but preventing the accumulation of toxic metabolites 
(with a statin) and replenishing end-product corrects the cutaneous phenotype.
The lack of efficacy of cholesterol alone is not due to the absence of LDL receptors in 
epidermis, given that the keratinocyte is able to incorporate NBD-labeled cholesterol (Man 
et al., 1993; Mao-Qiang et al., 1995). Rather, the response to dual- rather than mono-therapy 
probably reflects both the sterol depletion and metabolite accumulation that result from 
pathogenic mutations in enzymes of cholesterol synthesis, including CHILD syndrome 
(Porter and Herman, 2011). Blockade of metabolite production alone, however, is also 
insufficient. Indeed, normal mouse skin treated with topical statins develops ichthyosiform 
changes (Feingold et al., 1991; Menon et al., 1992a), reflecting the key role of cholesterol in 
the epidermal barrier (Elias, 2006; Feingold et al., 1990). Statin-induced cholesterol 
deficiency leads to decreased number and internal contents of epidermal lamellar bodies, as 
well as altered lamellar bilayer architecture, but no evidence of cytotoxicity (Feingold et al., 
1990; Menon et al., 1992a). In contrast, lesional skin from both CHILD patients also display 
much more severe alterations in the lamellar body secretory system, indicative of 
metabolite-induced toxicity. In fact, the mild ultrastructural changes in clinically 
“unaffected” skin suggest cholesterol deficiency, not of accumulation of sterol precursors, 
and implicate toxic metabolites in causing the ichthyosiform changes. Accumulation of 4-
methyl and 4,4-dimethyl sterol metabolites has been shown in tissue samples from 
heterozygous mutant female Bpa/Str mouse models of CHILD syndrome (Liu et al., 1999), 
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although near-normal levels of cholesterol and only minimal elevations in sterol metabolites 
are found in serum in these mice and in individuals with CHILD syndrome (Hummel et al., 
2003; Porter and Herman, 2011). This discrepancy likely reflects the functional mosaicism 
and skewed X-inactivation with widespread expression of the normal allele outside of 
affected sites. Insertion of sterol metabolites into cell membranes is known to induce 
membrane functional abnormalities, as well as toxic effects on oxysterol generation, altered 
hedgehog pathway signalling, and accelerated degradation of HMG CoA reductase (Porter 
and Herman, 2011). The lack of hair growth in affected areas, despite skin normalization 
with lovastain/cholesterol treatment, provides evidence of the important role of cholesterol 
and hedgehog pathway signaling in hair follicle development (Chiang et al., 1999; 
Cunningham et al., 2009; St-Jacques et al., 1998).
Our pathway-based therapeutic approach represents an entirely new concept for the topical 
therapy of disorders of distal cholesterol metabolism. Because it is pathway- rather than 
mutation-specific, it has broad applicability within this pathway. Cholesterol and lovastatin 
are generic (i.e., relatively inexpensive); have a known safety profile; and are lipid-soluble, 
facilitating penetration across the stratum corneum. The cholesterol/statin combination 
would likely be useful for another, closely-related disorder in this pathway (Fig. 1), Conradi-
Hünermann-Happle syndrome (CDPX2), which similarly presents with bone malformations 
and patterned ichthyotic skin lesions, but without lateralization (Akiyama et al., 2009; 
Steijlen et al., 2007). In fact, topical application of an end-product plus an upstream pathway 
inhibitor could well be useful for the many syndromic and non-syndromic disorders of fatty 
acid and ceramide metabolism. Metabolite-induced toxicity (with variable levels of pathway 
product depletion) has been described in several other syndromic, lipid metabolic disorders 
leading to ichthyotic manifestations, including the relatively common recessive X-linked 
ichthyosis, SjÖgren-Larsson syndrome, neutral lipid storage disease (Chanarin-Dorfman 
syndrome), type II (acute infantile neuronopathic) Gaucher disease, and Refsum disease (rev 
in (Elias et al., 2010; Elias et al., 2008). In theory, a comparable transdermal approach might 
also benefit the extracutaneous manifestations of these syndromic disorders, since the 
topical route would allow both the statin and cholesterol to bypass hepatic first-pass 
metabolism.
We also addressed the distribution of CHILD syndrome lesions through ultrastructural 
analysis and gene inactivation studies. Given that the NSHDL gene resides on Xq28, its 
expression is subject to X-inactivation. Sequencing of genomic DNA from cultured 
keratinocytes of the “unaffected” and “affected” sides both showed approximately equal 
amounts of mutant and normal gene. However, sequencing of expressed DNA from 
keratinocytes from lesional skin showed mutant NSDHL, whereas from keratinocytes of 
clinically normal contralateral skin revealed only the wild type NSDHL. We speculate that 
the mild abnormalities seen in ultrastructural analysis of ‘uninvolved skin’, in which 
cultured keratinocytes only express the normal allele, could reflect a residual population of 
keratinocytes expressing the mutant allele that is below our limit of detection by sequencing 
(i.e., <5%). Interestingly, fibroblasts from the clinically affected skin demonstrated both 
mutant and wild type NSDHL sequences, and fibroblasts from the clinically-normal side 
expressed only the normal genotype, accounting for the concordance of the clinical and 
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genotypic expression. The exclusive expression of the normal allele in keratinocytes and 
fibroblasts from the unaffected side explains the favorable outcome of full-thickness grafts 
from the unaffected to the affected side (König, et al., 2010). Indeed, our patient #1 had a 
full-thickness flap from the unaffected to the affected side at the midline of the abdomen 
performed during her procedure to debulk the verruciform xanthomatosis; this flapped skin 
was clinically normal at 6 months after surgery when the topical lovastatin/cholesterol 
therapy was initiated and remains clinically normal.
While culture of keratinocytes can offer a potential selective growth advantage of lesional or 
wild type cells, the strictly mutant or wild type sequence, respectively, in keratinocytes of 
lesional vs. clinically normal skin provides evidence that neither predominates in culture. 
Although one might consider segregation of affected keratinocytes as a mechanism for the 
observed expression patterns, exclusive expression of the wild type allele in both 
keratinocytes and fibroblasts on the unaffected side instead suggests preferential clearance 
of affected cells. Similarly, the skewing of X-inactivation in peripheral blood leukocytes is 
consistent with overall depletion of affected cells (Sun and Tsao, 2008). Preferential 
clearance of mutant cells postnatally has recently been described in the liver and brain of the 
Bpa mouse model of CHILD syndrome (Cunningham et al., 2009), although it should be 
noted that the mouse model does not show the lateralization of human CHILD syndrome. 
Although the mechanism of this preferential clearance and resultant lateralization remains 
unknown, its elucidation could increase our understanding of spatial organization during 
embryogenesis.
MATERIALS & METHODS
Patient Recruitment, Clinical Assessment and Genetic Analysis
Following institutional approval of experiments, written informed patient consent (and in the 
case of Patient 1 parental consent) and adherence to the Helsinki Guidelines, blood was 
drawn from both patients for genetic analysis to identify the NSHDL mutation. In addition, 
baseline photographs and biopsies of lesional and contralateral nonlesional skin were 
obtained for routine histology and electron microscopy. At both sites 3 physicians (3 
dermatologists in the Canary Islands and a dermatologist and two pediatricians in the U.S.) 
each saw the patients at each visit. All independently judged the progress on a global basis, 
rating erythema, scaling and thickening as 0 to 4+. For mutation analysis, DNA was 
extracted from peripheral blood leukocytes by salt precipitation. All coding exons (from 3 to 
9), including splice sites, were amplified by PCR (M13-tailed primer sequences and PCR 
protocol on request). PCR products were sequenced with universal M13-F and M13-R 
primers using the BigDye terminator v1.1 cycle sequencing kit (Applied Biosystems, Foster 
City, CA, USA). The mutation nucleotide position is based on NCBI-reference sequence 
BC007816.
Treatment Protocol
Prior to application, only bland emollients were applied; these were stopped for the trial and 
have not been restarted. A lovastatin 2%/cholesterol 2% suspension in paraben-preserved 
water was applied to the lesions of both patients twice daily for the first 6 months (total 
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applications limited to 30 cc monthly), and then tapered to maintain control. The 
compounded lotion was made with an identical formulation at both sites by grinding up 
lovastatin tablets (5 g), combining with cholesterol NF powder 5g, and mixing for at least 3 
mins with an electronic mortar and pestle to bring to full 240 cc in preserved water 
(www.markdrugs.com). Patients were observed at 6–8 weeks, 3 months, and then at 3-
month intervals for clinical changes as well as potential adverse effects.
Assessment of Ultrastructural Pathology
After aldehyde pre-fixation, skin biopsies were processed for H&E staining, or post-fixed in 
either osmium tetroxide or ruthenium tetroxide (to visualize lamellar bilayer architecture), 
and embedded in Epoxy resin (Hou et al., 1991). An additional piece was processed for 
ultrastructural cytochemistry utilizing the lipid secretory marker, acidic lipase (Menon et al., 
1992b). Ultrathin sections were examined in a Zeiss electron microscope, operated at 60 
KV.
Investigation of Gene Inactivation
Skin samples for keratinocyte and fibroblast cultures were obtained from lesional (left 
inguinal) and nonlesional (right inguinal) sites of Patient #1. Epidermis and dermis were 
separated after overnight incubation in Dispase® at 4°C. Keratinocyte and fibroblast 
suspensions, obtained by trypsinization, were cultured (Rheinwald and Green, 1975). 
Genomic DNA extracted from affected and unaffected keratinocytes was analyzed for the c.
248G>A mutation using the NSDHL exon 4 genomic PCR primers as described above. 
Total RNA was isolated and purified from the cultured cells with an RNeasy Kit (Qiagen, 
Valencia, CA, USA), and used to synthesize cDNA using a SuperScript® III First-Strand 
Synthesis System (Invitrogen, Carlsbad, CA, USA). In brief, 1.5-2 μg of total RNA was 
mixed with random primers and dNTPs, with incubation for 5 min at 65°C, followed by 
cooling. The cDNA was synthesized by adding SuperScript and incubation at 50°C for 50 
min, followed by 5 min incubation at 85°C. After removal of the remaining RNA with 
RNase H, 10–200 ng of the cDNA was used for PCR reactions. RT-PCR was performed on 
the cDNA using primers in exon 4 and 5 flanking the mutation (NSDHL4cF 5’-
TGGATTCCTGGGGCAGCAC-3’ and NSDHL5cR 5’-
TTACTGGATGGTGGGGGTGAC-3’, PCR-protocol on request). PCR products were 
sequenced directly using the PCR primers with the BigDye terminator v1.1 cycle sequencing 
kit (Applied Biosystem). For analysis of X-inactivation, the polymorphic CAG-repeat in 
exon 1 of the AR gene was PCR-amplified after digestion with the methylation-sensitive 
enzymes, HhaI and HpaII (Fearon et al., 1987).
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Abbreviations
CHILD Congenital hemidysplasia, Ichthyosis and Limb Defects
EBP emopamil binding protein
NSDHL NAD(P)H steroid dehydrogenase-like
SC stratum corneum
SG stratum granulosum
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Figure 1. The Cholesterol Biosynthetic Pathway
HMG-CoA reductase is a rate-limiting step early in the cholesterol biosynthetic pathway, 
which is inhibited by statins. CHILD syndrome results from mutations in NAD(P)H steroid 
dehydrogenase-like (NSDHL), which prevent the post-lanosterol generation of cholesterol, 
potentially leading to pathway-product deficiency in addition to metabolite accumulation. 
Conradi-Hünermann-Happle syndrome is due to mutations in a gene encoding emopamil 
binding protein (EBP), which acts distal to NSDHL in cholesterol biosynthesis.
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Figure 2. Clinical and Histologic Improvement with Topical Applications of Lovastatin/
Cholesterol
a: Treated skin of Patient #1. b: Treated skin of Patient #2. c. Histopathologic evaluation of 
lesional skin of Patient #2 at baseline (left) showed marked epidermal acanthosis with 
psoriasiform hyperplasia. The granular layer was absent, and the stratum corneum showed 
parakeratosis and retention hyperkeratosis. Bar = 25 μm. By approximately 3 months after 
treatment initiation (right), the epidermis was of normal thickness with regular 
orthokeratinization and a normal granular layer. Bar = 7 μm.
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Figure 3. Ultrastructural Normalization from Pathogenesis-Based Therapy in CHILD Syndrome
a and b: Pre-treatment biopsies show prominent abnormalities in epidermal lamellar body 
morphology (asterisks) and secretion in the stratum granulosum (SG). c: Impaired secretion 
results in entombment of unsecreted organelle contents within corneocytes (SC, solid 
arrows), reduced lamellar material in the SC interstices (open arrows), with massive 
distended foci of non-lamellar/amorphous material between corneocytes (asterisks). Post-
treatment biopsies (d and e) show substantial improvement in lamellar body contents (e) and 
secretion, but some foci of non-lamellar material persist (d, open arrows). a, b, and e: 
osmium tetroxide post-fixation; c and d: ruthenium tetroxide post-fixation. Bars: a = 0.2 μm; 
b = 0.5 μm; c = 0.2 μm; d and e = 0.1 μm.
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Figure 4. Ultrastructural Cytochemical Evidence of Improved Lamellar Body Secretion in 
Treated Skin
a: Pre-treatment biopsy, assessed with an ultrastructural marker of lamellar body contents, 
shows much retained (unsecreted) lamellar body contents within cornified cells (SC, 
arrows). Open arrows indicate focal sites where organelle contents have been secreted. b: 
Post-treatment biopsy reveals that most enzyme activity has been secreted (exteriorized) 
(arrows). Osmium tetroxide post-fixation. Bars: a: 0.5 μm; b = 0.25 μm.
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Figure 5. Clinically ‘Unaffected’ Epidermis of CHILD Syndrome Shows Abnormalities of the 
Lamellar Body Secretory System
Most of the lamellar bodies in the stratum granulosum (SG) display abnormal internal 
contents (c, asterisks). Lamellar body secretion is partially impaired, with entombment of 
some organelles (a, open arrows) and retained acidic lipase activity in some corneocytes, as 
shown by ultrastructural cytochemistry (b, open arrows). Note also the inhomogeneous 
distribution of secreted enzyme activity (b, arrows). Bars: a = 0.1 μm, b = 0.5 μm, c = 0.2 
μm.
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Figure 6. NSDHL Gene Expression
a. Sequences of cDNA obtained from cultured keratinocytes and fibroblasts in unaffected 
(upper panel) and affected (lower panel) areas of the skin. There is clear exclusive 
expression of the mutant c.248G>A allele in keratinocytes taken from affected skin, whereas 
fibroblasts from this area express both the mutant and the normal allele. In the unaffected 
areas only the wild type is found in keratinocytes as well as fibroblasts. b. Genomic DNA 
sequences obtained from peripheral blood leukocytes, unaffected and affected keratinocytes 
respectively. All traces show the presence of both wild type and mutant alleles. Arrows 
point to the mutant residue.
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